Kurt Brykman Bio

Mr. Brykman is a proven healthcare executive who has built a career on business transformations and turnarounds along with a strong track record of achieving revenue and EBITDA growth. Mr. Brykman’s expertise spans product, service and consulting businesses in industries ranging from pharmaceutical healthcare to consumer OTC products. He has worked with DFW since 2018 and currently serves as board member of INSIGHT2PROFIT, a DFW IV portfolio service company focused on delivering EBITDA growth for clients through implementation and management of pricing strategies. Prior to his current board assignment, he served as a board member for Lotus Clinical Research, a current DFW V portfolio company that was merged with Evolution Reseach Group earlier this year and an integral board member of RQM+, a highly successful DFW VI portfolio company which was exited in 2021. Prior to working with DFW, Mr. Brykman was the CEO of Kinapse, a London based life science company that specializes in worldwide regulatory affairs outsourcing for biopharma companies. Prior to Kinapse, he was the COO of Medpace, a specialty clinical research organization which provides expertise in executing scientifically challenging trials. Prior to that, he spent 9 years as an Officer and Divisional President of PAREXEL International, the 3rd largest CRO worldwide, where he successfully ran the PAREXEL Consulting, PAREXEL Medical Communications and PAREXEL Late Phase Clinicals business units. Early in his career, Mr. Brykman spend over a decade at Schering Plough’s large over-the-counter medicines business where he ran the worldwide Coppertone franchise of sunscreens, sunblocks and dermatology-focused products. He received his MBA from the J. L. Kellogg Graduate School of Management at Northwestern University in Chicago and is a graduate of Michigan State University with a BS degree in Mathematics and Business.